Randomized phase II trial of capecitabine and lapatinib with or without cixutumumab in patients with HER2+ breast cancer previously treated with trastuzumab and an anthracycline and/or a taxane: NCCTG N0733 (Alliance)

Authors :: Lynn M. Flickinger
Wilma L. Lingle
Paul Haluska
Monica M. Reinholz
Beiyun Chen
Helen X. Chen
Donald W. Northfelt
Amylou C. Dueck
Christine M. Pellegrino
Albert M. Bernath
Kathleen S. Tenner
Edith A. Perez
Robert W. Sponzo
Karla V. Ballman
Piyawan Tienchaiananda
Hannah M. Linden
Matthew P. Goetz
Xiaonan Hou
Source :: Journal of Clinical Oncology. 32:632-632
Publication Year :: 2014
Publisher :: American Society of Clinical Oncology (ASCO), 2014.
Abstract: 632 Background: Crosstalk between the insulin-like growth factor (IGF) and HER2 pathways in multiple preclinical models suggest a mechanism of resistance to HER2-targeted therapy. Cixutumumab (CIX,...

Full Text Access

Tools